Literature DB >> 12134948

Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.

Fuxing Tang1, Ronald T Borchardt.   

Abstract

PURPOSE: To elucidate the efflux transporter(s) responsible for restricting the permeation of a coumarinic acid-based cyclic prodrug of the opioid peptide DADLE (CD) thorough Caco-2 cell monolayers.
METHODS: The cellular permeability characteristics of CD were investigated using Caco-2 cells, Madin-Darby canine kidney-wild type II cells (MDCK-WT). MDCK cells transfected with the human MDR1 gene (MDCK-MDR1), and MDCK cells transfected with human MRP2 gene (MDCK-MRP2). These cells were grown as monolayers onto microporous membranes. The disappearance from the donor side and appearance on the receiver side of CD were monitored by HPLC. The substrate activity of CD for P-gp was determined by using GF120918. a known P-gp specific inhibitor. The substrate activity of CD for MRP2 was determined by using cyclosporin A (CsA), a known MRP2 and P-gp inhibitor.
RESULTS: In Caco-2 cells, the ratio of the apparent permeability coefficients (Papp) of CD flux in the basolateral (BL) to apical (AP) direction vs. the flux in the AP-to-BL direction (Papp-BL-to-AP/Papp AP-to-BL) was 71. In the presence of GF120918 (2 microM), the Papp BL-to-AP/Papp AP-to-BL ratio was decreased to 16. In the presence of CsA (25 microM), the ratio was decreased to 5.6. In MDCK-WT. MDCK-MDR1, and MDCK-MRP2 cells, the Papp BL-AP/Papp AP-to-BL ratios of CD were 13, 35, and 22, respectively. CsA (25 microM) greatly decreased the Papp BL-P-AP/Papp AP-to-BL ratios in MDCK-WT and MDCK-MDR1 cells to 1.5 and 3.2, respectively. However, in MDCK-MRP2 cells. CsA (25 microM) decreased the ratio only to 11. A mixture of GF120918 (2 microM) and CsA (25 microM) decreased the Papp BL-to-AP/Papp AP-to-BL ratios of CD in MDCK-WT, MDCK-MDR1, and MDCK-MRP2 cells to 1.4, 2.7, and 5.4. respectively.
CONCLUSIONS: These data suggest that CD is a good substrate for both P-gp and MRP2 and that the restricted permeation of this cyclic prodrug in Caco-2 cells and in the intestinal mucosa is probably due to its substrate activities for both of these efflux transporters.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134948     DOI: 10.1023/a:1016196514217

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

Review 1.  Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond.

Authors:  P Artursson; R T Borchardt
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

2.  Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats.

Authors:  C G Dietrich; D R de Waart; R Ottenhoff; I G Schoots; R P Elferink
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

3.  P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels.

Authors:  P Anderle; E Niederer; W Rubas; C Hilgendorf; H Spahn-Langguth; H Wunderli-Allenspach; H P Merkle; P Langguth
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

Review 4.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.

Authors:  J König; A T Nies; Y Cui; I Leier; D Keppler
Journal:  Biochim Biophys Acta       Date:  1999-12-06

5.  Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport.

Authors:  P L Jansen; W H Peters; W H Lamers
Journal:  Hepatology       Date:  1985 Jul-Aug       Impact factor: 17.425

6.  Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B.

Authors:  A T Nies; T Cantz; M Brom; I Leier; D Keppler
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

7.  Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators.

Authors:  J Hunter; M A Jepson; T Tsuruo; N L Simmons; B H Hirst
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

8.  Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.

Authors:  Fuxing Tang; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

9.  Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.

Authors:  A Bak; O S Gudmundsson; G J Friis; T J Siahaan; R T Borchardt
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

10.  Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.

Authors:  K I Hosoya; K J Kim; V H Lee
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

View more
  10 in total

Review 1.  Cyclization-activated prodrugs.

Authors:  Paula Gomes; Nuno Vale; Rui Moreira
Journal:  Molecules       Date:  2007-11-12       Impact factor: 4.411

Review 2.  Strategic approaches to optimizing peptide ADME properties.

Authors:  Li Di
Journal:  AAPS J       Date:  2014-11-04       Impact factor: 4.009

3.  Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery.

Authors:  Shuanghui Luo; Viral S Kansara; Xiaodong Zhu; Nanda K Mandava; Dhananjay Pal; Ashim K Mitra
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

4.  Targeted lipid based drug conjugates: a novel strategy for drug delivery.

Authors:  Aswani Dutt Vadlapudi; Ramya Krishna Vadlapatla; Deep Kwatra; Ravinder Earla; Swapan K Samanta; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2012-06-09       Impact factor: 5.875

5.  Transport characteristics of fexofenadine in the Caco-2 cell model.

Authors:  Niclas Petri; Christer Tannergren; David Rungstad; Hans Lennernäs
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

6.  A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.

Authors:  Hui Ouyang; Fuxing Tang; Teruna J Siahaan; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

7.  Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?

Authors:  Fuxing Tang; Kazutoshi Horie; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

8.  Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

Review 9.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

10.  Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers.

Authors:  Zufan Debebe; Sergei Nekhai; Meseret Ashenafi; David B Lovejoy; Danuta S Kalinowski; Victor R Gordeuk; W Malcolm Byrnes; Des R Richardson; Pradeep K Karla
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-08-15       Impact factor: 3.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.